Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study.

Trial Profile

Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Results (n=195) post-hoc analysis performed on a subset of patient with gene expression profiling on tissues from this trial to identify markers associated with progression-free survival (PFS) and treatment response, were published in the European Journal of Cancer.
    • 26 Sep 2016 Results for secondary endpoints HRQOL and neurocognitive functioning, published in the Lancet Oncology Journal.
    • 26 Sep 2016 Results of this trial, published in the Lancet Oncology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top